| Recruiting | A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radi NCT07070076 | Li Qiang | N/A |
| Not Yet Recruiting | Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer NCT07537946 | Tongji Hospital | Phase 3 |
| Not Yet Recruiting | Denosumab Strategy for Liver Cancer With Bone Metastases NCT07537972 | Tongji Hospital | Phase 2 |
| Not Yet Recruiting | Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases NCT07537959 | Tongji Hospital | N/A |
| Not Yet Recruiting | Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy NCT07493668 | CHA University | Phase 2 |
| Not Yet Recruiting | Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line NCT07537777 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Recruiting | Scout Dose of Resin Microspheres NCT07476651 | Seoul National University Hospital | N/A |
| Recruiting | A Phase 1 Study of the Safety and Tolerability of CTX-10726 NCT07419841 | Compass Therapeutics | Phase 1 |
| Not Yet Recruiting | Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer NCT07075120 | University of Hawaii | Phase 1 |
| Not Yet Recruiting | GNB4 and Riplet Gene Methylation Combined Detection Kit for Hepatocellular Carcinoma Recurrence Monitoring NCT07489768 | Tongji Hospital | — |
| Not Yet Recruiting | Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in NCT07481032 | Nanfang Hospital, Southern Medical University | N/A |
| Not Yet Recruiting | Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE) NCT07495579 | Asan Medical Center | Phase 2 |
| Not Yet Recruiting | Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresecta NCT07487402 | Zhejiang University | EARLY_Phase 1 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepa NCT07490262 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Phase 2 / Phase 3 |
| Not Yet Recruiting | The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities NCT07381634 | First Affiliated Hospital of Wenzhou Medical University | Phase 2 |
| Recruiting | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Partic NCT07291076 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Not Yet Recruiting | PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After NCT07463248 | Wang Xin | Phase 2 |
| Not Yet Recruiting | Computer Guided Microwave Liver Ablation NCT07226869 | NE Scientific INC | N/A |
| Not Yet Recruiting | HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion NCT07466225 | Peking University | — |
| Not Yet Recruiting | A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hep NCT07392866 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 2 / Phase 3 |
| Recruiting | Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma NCT07413354 | Tongji Hospital | Phase 2 |
| Not Yet Recruiting | Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Por NCT07483359 | First Hospital of China Medical University | Phase 2 |
| Not Yet Recruiting | Validation of Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma NCT07414433 | University of Belgrade | — |
| Not Yet Recruiting | Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellula NCT07417800 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Not Yet Recruiting | A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Adv NCT07422753 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Active Not Recruiting | Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca NCT07493070 | Fujian Medical University Union Hospital | N/A |
| Recruiting | Evaluating the roLe of Multiplexed PET Imaging in the Detection and Staging of hepatocellulaR Carcinoma and gA NCT07178587 | Nantes University Hospital | N/A |
| Not Yet Recruiting | International Study on Treatment of Liver (HCC) Patients With IRE NCT07192731 | Angiodynamics, Inc. | N/A |
| Not Yet Recruiting | FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma NCT07314372 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 |
| Not Yet Recruiting | SBRT Versus Surgical Resection for Small HCC NCT07381660 | Sun Yat-sen University | Phase 3 |
| Active Not Recruiting | Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectab NCT07380633 | Sun Yat-sen University | Phase 2 |
| Recruiting | Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Car NCT07469319 | University of Aarhus | N/A |
| Recruiting | Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma NCT07154082 | Wei Zhang | Phase 2 |
| Not Yet Recruiting | TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Crite NCT07268131 | Fudan University | N/A |
| Recruiting | A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition NCT07291141 | Mattias Ekstedt | — |
| Recruiting | NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy NCT07365930 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | — |
| Recruiting | Sapu003 in Advanced mTOR-sensitive Solid Tumors NCT07369505 | SAPU NANO (US) LLC | Phase 1 |
| Recruiting | NWRD06 DNA Plasmid for HCC After Curative Resection. NCT07324304 | Newish Technology (Beijing) Co., Ltd. | Phase 2 |
| Recruiting | Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing He NCT07436845 | Nanfang Hospital, Southern Medical University | — |
| Recruiting | A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies NCT07197554 | SEED Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Pr NCT06680258 | Tempest Therapeutics | Phase 3 |
| Not Yet Recruiting | A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma NCT07239986 | Broadenbio Ltd., Co. | Phase 2 |
| Recruiting | DEB-TACE vs cTACE in HCC After TIPS NCT07322848 | First Affiliated Hospital, Sun Yat-Sen University | Phase 3 |
| Not Yet Recruiting | TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Re NCT07253220 | Sun Yat-sen University | N/A |
| Recruiting | Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab NCT07176650 | Shanghai Henlius Biotech | Phase 1 |
| Recruiting | Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellul NCT07331883 | Ruijin Hospital | Phase 2 |
| Recruiting | Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN NCT06735560 | Nantes University Hospital | N/A |
| Recruiting | Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors NCT07337460 | Northern Jiangsu People's Hospital | Phase 2 |
| Not Yet Recruiting | A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Ca NCT07156617 | Xuhua Duan | — |
| Withdrawn | A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab NCT06994299 | Weill Medical College of Cornell University | Phase 2 |
| Not Yet Recruiting | CT Volume Measurement of Hepatocellular Carcinoma NCT07183566 | Assiut University | — |
| Recruiting | An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Th NCT07315633 | University Hospital, Ghent | — |
| Recruiting | Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previousl NCT07192185 | Sun Yat-sen University | Phase 2 |
| Recruiting | A Phase I Study of CREPT-618 in Locally Advanced HCC NCT07364357 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 |
| Recruiting | A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-V NCT07495215 | Yinghua Xu | Phase 1 / Phase 2 |
| Recruiting | Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With NCT06726161 | RayzeBio, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France NCT07038863 | Hospices Civils de Lyon | N/A |
| Not Yet Recruiting | Role of Long Noncoding RNA LINC01134 in Metastasis of Hepatitis C Virus-related Hepatocellular Carcinoma NCT07130474 | Sohag University | — |
| Recruiting | Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion NCT07170345 | Chinese Academy of Sciences | — |
| Completed | Interventional AI-Human Collaboration for Liver Tumor Diagnosis NCT07153783 | Shengjing Hospital | N/A |
| Not Yet Recruiting | Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy NCT07151326 | National Health Research Institutes, Taiwan | Phase 2 |
| Not Yet Recruiting | Post-Radical Treatment Antiviral Strategies in HBV-Related Liver Cancer: Impact on Tumor Prognosis NCT07120750 | Shenzhen Third People's Hospital | — |
| Recruiting | Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellu NCT07337421 | Northern Jiangsu People's Hospital | Phase 2 |
| Recruiting | The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine NCT07150624 | Anhui Provincial Hospital | Phase 4 |
| Not Yet Recruiting | A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With R NCT07115550 | Huai'an First People's Hospital | N/A |
| Not Yet Recruiting | A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE f NCT07150377 | The Second Affiliated Hospital of Shandong First Medical University | Phase 2 |
| Not Yet Recruiting | A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With NCT07128251 | Anhui Provincial Hospital | Phase 2 |
| Recruiting | Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Tre NCT07100392 | Fudan University | Phase 2 |
| Recruiting | Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma NCT07077356 | West China Hospital | Phase 1 |
| Active Not Recruiting | A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-L NCT07138885 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy NCT07077369 | West China Hospital | Phase 1 |
| Not Yet Recruiting | The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcin NCT07078292 | Tianjin Medical University Cancer Institute and Hospital | — |
| Not Yet Recruiting | Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection NCT07077798 | Wan-Guang Zhang | N/A |
| Recruiting | Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogre NCT06841172 | Shandong Cancer Hospital and Institute | Phase 3 |
| Recruiting | A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. NCT07052253 | Akeso | Phase 2 |
| Recruiting | Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC NCT07186621 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 |
| Enrolling By Invitation | JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study NCT06882876 | Xiangya Hospital of Central South University | Phase 1 |
| Not Yet Recruiting | Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Foll NCT07027436 | Hamilton Health Sciences Corporation | Phase 3 |
| Recruiting | Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti- NCT07047586 | Fudan University | Phase 2 |
| Recruiting | Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radi NCT07059936 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Not Yet Recruiting | FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Trea NCT07012798 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression NCT07327034 | Abbisko Therapeutics Co, Ltd | Phase 2 |
| Recruiting | Streamlining Radioembolization for Small HCC NCT06979219 | Seoul National University Hospital | — |
| Not Yet Recruiting | Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs NCT07010588 | Peking University People's Hospital | N/A |
| Not Yet Recruiting | TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC NCT06990620 | Fudan University | Phase 1 |
| Not Yet Recruiting | Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular NCT06994572 | Captor Therapeutics S.A. | Phase 1 |
| Recruiting | Electronic Symptom Monitoring of Patient-Reported Outcomes Among Patients With Hepatocellular Carcinoma During NCT06938945 | Wei Xiaoping | N/A |
| Recruiting | Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma NCT06893887 | Nanjing Tianyinshan Hospital | N/A |
| Recruiting | On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer NCT06877637 | Region Skane | — |
| Recruiting | Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Be NCT06605664 | Chang Gung Memorial Hospital | Phase 2 |
| Recruiting | Multiparametric MRI for Characterization of Hepatocellular Carcinoma NCT06999174 | University Hospital Muenster | — |
| Not Yet Recruiting | Relationship Between FGF19 Overexpression and Disease Prognosis NCT06938451 | Beijing Tsinghua Chang Gung Hospital | — |
| Not Yet Recruiting | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a NCT06841185 | Shanghai Henlius Biotech | Phase 3 |
| Recruiting | Same-day Radioembolization for Large HCC NCT06944483 | Seoul National University Hospital | — |
| Not Yet Recruiting | Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radic NCT06923176 | Zhiyun Yang | Phase 4 |
| Recruiting | Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma NCT06911255 | Yoon Jun Kim | Phase 1 / Phase 2 |
| Active Not Recruiting | Predictive Value of Albumin - Bilirubin Score and CRP - Albumin - Lymphocyte Index for HCC Prognosis After Rad NCT06934070 | Qiang Xu | — |
| Not Yet Recruiting | Characteristic and Survival Outcomes in Hepatocellular Carcinoma Patients: on Top of Viral Hepatitis Versus Co NCT06871930 | Assiut University | — |
| Recruiting | The Dragon PLC Trial (DRAGON-PLC) NCT06914648 | Maastricht University | N/A |
| Not Yet Recruiting | The Epidemiology of Patients Treated With ATZ+BEV in Real Life Setting NCT06903663 | Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor | — |
| Recruiting | HAIC Combined with Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03) NCT06860490 | Fudan University | Phase 2 |
| Recruiting | Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria NCT06773845 | Seoul National University Hospital | Phase 2 |
| Active Not Recruiting | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer NCT06521567 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Not Yet Recruiting | MSEPT9 Biomarker for Predicting Hepatocellular Carcinoma Occurrence in Patients with Cirrhosis NCT06778317 | Central Hospital, Nancy, France | — |
| Recruiting | Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma NCT06741020 | Zhejiang Cancer Hospital | Phase 1 / Phase 2 |
| Recruiting | Amplitude-modulated Radiofrequency Electromagnetic Field Treatment for Advanced Hepatocellular Carcinoma (Immu NCT06821958 | Charite University, Berlin, Germany | N/A |
| Active Not Recruiting | Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicent NCT06842563 | Singlera Genomics Inc. | — |
| Recruiting | Exploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery NCT06861114 | Zhujiang Hospital | — |
| Terminated | A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurre NCT06851104 | Guangxi Medical University | Phase 2 |
| Recruiting | Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab NCT06961526 | Tanta University | N/A |
| Recruiting | A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions NCT06864195 | Imperial College London | — |
| Not Yet Recruiting | Ga-68 Dolacga PET Scan in HCC Under RFA NCT06792097 | National Taiwan University Hospital | — |
| Recruiting | Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk NCT06762782 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Not Yet Recruiting | Use of Machine-learning Algorithms, Biomarkers and Measures of Quality of Life to Personalize Medical Manageme NCT06774768 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | A Cell-free tsRNA Signature for Early Detection of Hepatocellular Carcinoma NCT07265271 | City of Hope Medical Center | — |
| Recruiting | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) NCT06695026 | Rznomics, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | The Use of AKR1B10 for Monitoring Postoperative Recurrence of Hepatocellular Carcinoma NCT06750159 | Peking Union Medical College Hospital | — |
| Recruiting | The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Pat NCT06746194 | Ruijin Hospital | — |
| Recruiting | Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant NCT06725121 | University Health Network, Toronto | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in t NCT06724263 | Tasly Biopharmaceuticals Co., Ltd. | Phase 2 |
| Recruiting | Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients W NCT06644937 | Zhujiang Hospital | Phase 2 / Phase 3 |
| Recruiting | Mts105 for Advanced Hepatocellular Carcinoma NCT06689540 | Shen Lin | Phase 1 |
| Recruiting | Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveill NCT06653062 | Tongji Hospital | — |
| Recruiting | Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma NCT06652243 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | EARLY_Phase 1 |
| Not Yet Recruiting | CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma NCT06641453 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Enrolling By Invitation | Streamlined Resin Y90 Radiation Segmentectomy for Small HCC NCT06618300 | UNC Lineberger Comprehensive Cancer Center | — |
| Not Yet Recruiting | Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCC NCT06639971 | Shanghai Zhongshan Hospital | — |
| Not Yet Recruiting | Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study NCT06685354 | Henan Cancer Hospital | Phase 2 |
| Recruiting | Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT NCT06664996 | West China Hospital | Phase 2 |
| Recruiting | Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patient NCT06594744 | Taipei Veterans General Hospital, Taiwan | Phase 4 |
| Recruiting | Ten-Year Outcomes of Operable Solitary Hepatocellular Carcinoma Patients: Impact of Tumor Size Over 6.5 cm and NCT06628661 | Chang Gung Memorial Hospital | — |
| Recruiting | PSMA PET for the Staging and Management of Hepatocellular Carcinoma NCT07019844 | VA Office of Research and Development | — |
| Recruiting | A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalim NCT06487559 | AbbVie | Phase 1 |
| Completed | A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given A NCT06345001 | Bayer | Phase 1 |
| Enrolling By Invitation | Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China NCT06712017 | GrandPharma (China) Co., Ltd. | — |
| Recruiting | Exploratory Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma NCT07378709 | University of Belgrade | — |
| Active Not Recruiting | HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC NCT06632106 | First Hospital of China Medical University | — |
| Recruiting | An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Charact NCT07101237 | Peking Union Medical College Hospital | — |
| Recruiting | Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90 NCT07303712 | Palo Alto Veterans Institute for Research | — |
| Completed | Individualized Surgical Guidance in HCC-BDTT NCT07483242 | First Affiliated Hospital, Sun Yat-Sen University | — |
| Recruiting | A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer NCT07224750 | City of Hope Medical Center | — |
| Recruiting | Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH) NCT07293468 | Tuen Mun Hospital | Phase 2 / Phase 3 |
| Active Not Recruiting | A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab T NCT06040099 | AstraZeneca | Phase 2 |
| Completed | Artificially Intelligent Model for Accurate Detection of HCC NCT06637059 | Zhejiang University | — |
| Terminated | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors NCT05909995 | Incyte Corporation | Phase 1 |
| Completed | Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma NCT07030842 | Tongji Hospital | — |
| Recruiting | Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform NCT05520099 | Elephas | — |
| Recruiting | Collection of Blood and Tissue Samples From Patients With Primary Liver Cancer. NCT06899854 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Recruiting | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Co NCT05824975 | GI Innovation, Inc. | Phase 1 / Phase 2 |
| Terminated | Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC) NCT05770882 | Great Novel Therapeutics Biotech & Medicals Corporation | Phase 1 / Phase 2 |
| Completed | Triple Recipient Strategy Using Split, Domino, and Auxiliary Techniques NCT06683820 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Completed | Single-Cell Profiling of Liver-infiltrating Immune Cells of Patients with NASH- and Virus-related HCC: Implica NCT06899763 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Recruiting | Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carci NCT06806579 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Withdrawn | A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the NCT04465734 | Shanghai Henlius Biotech | Phase 3 |
| Active Not Recruiting | Multimodal Machine Learning Characterization of Solid Tumors NCT04687969 | Ciprian Catana, MD, PhD | — |
| Recruiting | ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma NCT04634357 | Eureka Therapeutics Inc. | Phase 1 / Phase 2 |
| Completed | Dietary Intervention and Gut Microbiota in Hepatocellular Carcinoma (HCC) NCT07143955 | The First Hospital of Hebei Medical University | N/A |
| Active Not Recruiting | A Prospective Observational Study on Efficacy of TARE for Early Stage HCC NCT07278102 | Seoul National University Hospital | — |
| Recruiting | Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors NCT05176483 | Exelixis | Phase 1 |
| Active Not Recruiting | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours NCT05057013 | Cancer Research UK | Phase 1 / Phase 2 |
| Completed | TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma NCT07053202 | The First Hospital of Hebei Medical University | N/A |
| Completed | TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion NCT07075562 | The First Hospital of Hebei Medical University | N/A |
| Active Not Recruiting | A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma NCT05022927 | Chugai Pharmaceutical | Phase 1 |
| Active Not Recruiting | Radiofrequency Ablation Using Combined RF Energy Delivery Mode and Octopus Electrodes for Hepatocellular Carci NCT06682377 | Seoul National University Hospital | N/A |
| Active Not Recruiting | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellul NCT04639180 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Recruiting | Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC) NCT04601428 | Koo Foundation Sun Yat-Sen Cancer Center | EARLY_Phase 1 |
| Completed | Different Abbreviated MRI for Hepatocellular Carcinoma Diagnosis NCT06663904 | First Affiliated Hospital, Sun Yat-Sen University | — |
| Completed | The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined NCT07272265 | Sun Yat-sen University | N/A |
| Completed | Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function NCT04522908 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Enrolling By Invitation | FAST (Focused Abbreviated Screening Technique)-MRI Study NCT04539717 | Icahn School of Medicine at Mount Sinai | — |
| Recruiting | Liver Cancer Registry Platform NCT04510740 | iOMEDICO AG | — |
| Terminated | Y90 Radiation Segmentectomy vs SBRT for HCC NCT04235660 | Indiana University | N/A |
| Recruiting | A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tum NCT06636435 | Chiome Bioscience Inc. | Phase 1 |
| Completed | A Retrospective Cohort Study on Predicting Delayed Graft Function in Liver Transplant Patients with Hepatocell NCT06626724 | Jian You | — |
| Unknown | Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC NCT04241523 | Shanghai Zhongshan Hospital | Phase 2 |
| Unknown | Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma NCT04227808 | Shanghai Zhongshan Hospital | Phase 2 |
| Withdrawn | The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant Liver Tumors NCT04044326 | National Taiwan University Hospital | N/A |
| Unknown | Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma NCT05889949 | Sun Yat-sen University | — |
| Completed | IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC NCT03753659 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Completed | Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) NCT03510871 | National Health Research Institutes, Taiwan | Phase 2 |
| Completed | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Adva NCT03735628 | Bayer | Phase 1 |
| Withdrawn | Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With Doxorubicin NCT03452553 | Boston Scientific Corporation | N/A |
| Recruiting | Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC NCT06876753 | Zhongda Hospital | — |
| Completed | CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC NCT07449065 | First Affiliated Hospital, Sun Yat-Sen University | — |
| Recruiting | Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors w NCT06881433 | Zhongda Hospital | — |
| Recruiting | Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors w NCT06881446 | Zhongda Hospital | — |
| Unknown | Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After NCT05213637 | Chinese PLA General Hospital | Phase 2 |
| Completed | Study of BGB-A317 in Participants With Previously Treated Unresectable HCC NCT03419897 | BeiGene | Phase 2 |
| Completed | A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) NCT03412773 | BeiGene | Phase 3 |
| Completed | TACE for HCC by TANDEM and Idarubicin NCT03349957 | University Hospital, Montpellier | — |
| Terminated | The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects NCT03236649 | Beijing Shenogen Biomedical Co., Ltd | Phase 3 |
| Terminated | A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With th NCT03071094 | Transgene | Phase 1 / Phase 2 |
| Completed | Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by NCT02834546 | University Hospital, Bordeaux | — |
| Unknown | The Potential Role of Ga-68-PSMA in Staging, Restaging and Monitoring Response in Primary Liver Cancer: Compar NCT03138239 | Tel-Aviv Sourasky Medical Center | N/A |
| Completed | Comparing Diagnostic Accuracy for Liver Tumours Between the Combination of CEUS and CEMRI Versus CECT and CEMR NCT03267290 | National Taiwan University Hospital | N/A |
| Terminated | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma a NCT03144661 | Incyte Corporation | Phase 1 |
| Completed | A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC NCT03516071 | Zai Lab (Shanghai) Co., Ltd. | Phase 2 |
| Unknown | Comparing Re-TACE Versus SABR for Post-prior-TACE Incompletely Regressed HCC: a Randomized Controlled Trial (T NCT02921139 | Dalin Tzu Chi General Hospital | N/A |
| Completed | Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone NCT02562755 | SillaJen, Inc. | Phase 3 |
| Completed | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma NCT02508467 | Blueprint Medicines Corporation | Phase 1 |
| Completed | Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis NCT02794805 | Meridian Bioscience, Inc. | Phase 2 |
| Completed | Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplant NCT07418138 | Hu Liangshuo | — |
| Completed | FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression NCT02325739 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Efficacy of Loco-regional Treatment for Hepatocellular Carcinoma Prior to Living Donor Liver Transplantation i NCT02990351 | Ain Shams University | — |
| Completed | Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory NCT02188901 | Yonsei University | N/A |
| Withdrawn | Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unr NCT02406508 | Delcath Systems Inc. | Phase 2 |
| Completed | Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Ve NCT03007212 | Ain Shams University | Phase 4 |
| Completed | Can Quantitative MRI After cTACE Help Predict Survival ? NCT02173119 | Medical College of Wisconsin | — |
| Completed | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participan NCT02178722 | Incyte Corporation | Phase 1 / Phase 2 |
| Completed | Annexin A2 as a Novel Diagnostic Marker in Hepatocellular Carcinoma NCT02541149 | Ain Shams University | — |
| Completed | The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma NCT01972672 | Beijing Shenogen Biomedical Co., Ltd | Phase 2 |
| Unknown | A Study of DC-CIK to Treat Hepatocellular Carcinoma NCT01821482 | Guangxi Medical University | Phase 2 |
| Completed | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Soraf NCT01761266 | Eisai Limited | Phase 3 |
| Completed | Optimal Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension NCT01642446 | Sun Yat-sen University | N/A |
| Terminated | Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI NCT01433016 | Meridian Bioscience, Inc. | Phase 2 |
| Completed | A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) fo NCT01247298 | University of Alabama at Birmingham | EARLY_Phase 1 |
| Completed | AI Multitask Model for HCC Treatment NCT07157085 | Sun Yat-sen University | — |
| Completed | A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer NCT00355238 | Bristol-Myers Squibb | Phase 2 |
| Completed | Validation of the TRAIN-AI for the Risk of HCC Recurrence After Liver Transplantation NCT06799468 | European Hepatocellular Cancer Liver Transplant Group | — |
| Available | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory App NCT06751524 | Agenus Inc. | — |